Ocular Therapeutix, Inc. (OCUL): Price and Financial Metrics


Ocular Therapeutix, Inc. (OCUL): $3.88

-0.01 (-0.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OCUL to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

OCUL POWR Grades

  • OCUL scores best on the Value dimension, with a Value rank ahead of 46.68% of US stocks.
  • OCUL's strongest trending metric is Quality; it's been moving down over the last 177 days.
  • OCUL ranks lowest in Growth; there it ranks in the 14th percentile.

OCUL Stock Summary

  • OCUL's price/sales ratio is 6.02; that's higher than the P/S ratio of 80.65% of US stocks.
  • Over the past twelve months, OCUL has reported earnings growth of -35.67%, putting it ahead of 27.79% of US stocks in our set.
  • The volatility of OCULAR THERAPEUTIX INC's share price is greater than that of 76.77% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to OCULAR THERAPEUTIX INC are GH, EYPT, PLSE, ONDS, and IPWR.
  • OCUL's SEC filings can be seen here. And to visit OCULAR THERAPEUTIX INC's official web site, go to www.ocutx.com.

OCUL Valuation Summary

  • OCUL's price/sales ratio is 6.3; this is 23.53% higher than that of the median Healthcare stock.
  • Over the past 103 months, OCUL's price/sales ratio has gone down 2175.2.

Below are key valuation metrics over time for OCUL.

Stock Date P/S P/B P/E EV/EBIT
OCUL 2023-01-20 6.3 6.8 -5.3 -4.8
OCUL 2023-01-19 6.4 6.8 -5.3 -4.8
OCUL 2023-01-18 6.3 6.8 -5.3 -4.8
OCUL 2023-01-17 6.4 6.9 -5.4 -4.9
OCUL 2023-01-13 6.2 6.7 -5.2 -4.7
OCUL 2023-01-12 6.0 6.4 -5.0 -4.5

OCUL Growth Metrics

    Its year over year revenue growth rate is now at 123.01%.
  • Its 4 year cash and equivalents growth rate is now at -11.51%.
  • The year over year price growth rate now stands at -80.31%.
Over the past 67 months, OCUL's revenue has gone up $47,822,000.

The table below shows OCUL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 49.726 -57.798 -59.346
2022-06-30 49.914 -57.611 -32.501
2022-03-31 49.366 -66.791 -22.216
2021-12-31 43.522 -65.55 -6.553
2021-09-30 38.562 -56.643 -88.315
2021-06-30 32.285 -57.319 -102.916

OCUL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OCUL has a Quality Grade of C, ranking ahead of 60.31% of graded US stocks.
  • OCUL's asset turnover comes in at 0.155 -- ranking 219th of 682 Pharmaceutical Products stocks.
  • CASI, ONVO, and DRNA are the stocks whose asset turnover ratios are most correlated with OCUL.

The table below shows OCUL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.155 0.903 -1.479
2021-03-31 0.125 0.903 -1.953
2020-12-31 0.129 0.880 -2.245
2020-09-30 0.138 0.818 -1.315
2020-06-30 0.084 0.642 -1.377
2020-03-31 0.077 0.525 -1.196

OCUL Price Target

For more insight on analysts targets of OCUL, see our OCUL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $23.43 Average Broker Recommendation 1.43 (Moderate Buy)

OCUL Stock Price Chart Interactive Chart >

Price chart for OCUL

OCUL Price/Volume Stats

Current price $3.88 52-week high $6.53
Prev. close $3.89 52-week low $2.57
Day low $3.81 Volume 567,800
Day high $3.93 Avg. volume 657,728
50-day MA $3.18 Dividend yield N/A
200-day MA $3.99 Market Cap 298.80M

Ocular Therapeutix, Inc. (OCUL) Company Bio


Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. The company was founded in 2006 and is based in Bedford, Massachusetts.


OCUL Latest News Stream


Event/Time News Detail
Loading, please wait...

OCUL Latest Social Stream


Loading social stream, please wait...

View Full OCUL Social Stream

Latest OCUL News From Around the Web

Below are the latest news stories about OCULAR THERAPEUTIX INC that investors may wish to consider to help them evaluate OCUL as an investment opportunity.

Ocular Therapeutix Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones

Dextenza Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6 million, Growing Approximately 14% Over Previous Quarter and Approximately 11% Over Same Quarter of Prior Year Dextenza Net Product Revenue for the Year Ending 2022 is Estimated to be $50.2 million, Representing Growth of Approximately 20% Over Prior Year 10-month Interim Data from the U.S.-based Phase 1 Clinical

Wallstreet:Online | January 6, 2023

Ocular Therapeutix™ Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones

Dextenza® Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6 million, Growing Approximately 14% Over Previous Quarter and Approximately 11% Over Same Quarter of Prior Year Dextenza Net Product Revenue for the Year Ending 2022 is Estimated to be $50.2 million, Representing Growth of Approximately 20% Over Prior Year 10-month Interim Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Wet AMD to be Presented at the

Yahoo | January 6, 2023

Can you now get a good deal on Ocular Therapeutix Inc.’s shares?

Ocular Therapeutix Inc. (NASDAQ:OCUL) marked $3.17 per share on Wednesday, up from a previous closing price of $2.79. While Ocular Therapeutix Inc. has overperformed by 13.62%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, OCUL fell by -56.87%, with highs and lows ranging from $7.36 to […]

US Post News | January 5, 2023

Ocular Therapeutix Inc. (NASDAQ:OCUL) Slides 0.36 Percent In Recent Trade, What Can We Expect Next?

Ocular Therapeutix Inc. (NASDAQ:OCUL) traded at $2.81 at close of the session on Friday, 12/30/22, made an upward move of 0.36% on its previous day’s price. Looking at the stock we see that its previous close was $2.80 and the beta (5Y monthly) reads 1.48 with the day’s price range being $2.66 – $2.82. In … Ocular Therapeutix Inc. (NASDAQ:OCUL) Slides 0.36 Percent In Recent Trade, What Can We Expect Next? Read More »

Stocks Register | January 3, 2023

Ocular Therapeutix Inc. (NASDAQ: OCUL) Is Down -2.20% Over The Last Week, But Will It Continue To Climb?

Ocular Therapeutix Inc. (NASDAQ:OCUL)’s traded shares stood at 0.5 million during the last session, with the company’s beta value hitting 1.35. At the close of trading, the stock’s price was $2.67, to imply a decrease of -3.61% or -$0.1 in intraday trading. The OCUL share’s 52-week high remains $7.38, putting it -176.4% down since that … Ocular Therapeutix Inc. (NASDAQ: OCUL) Is Down -2.20% Over The Last Week, But Will It Continue To Climb? Read More »

Marketing Sentinel | December 24, 2022

Read More 'OCUL' Stories Here

OCUL Price Returns

1-mo 38.08%
3-mo 7.48%
6-mo -12.22%
1-year -27.48%
3-year -11.62%
5-year -34.13%
YTD 38.08%
2022 -59.68%
2021 -66.33%
2020 424.05%
2019 -0.75%
2018 -10.56%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7761 seconds.